LifeMD (NASDAQ:LFMD) Lowered to “Strong Sell” Rating by Zacks Research

Zacks Research lowered shares of LifeMD (NASDAQ:LFMD) from a hold rating to a strong sell rating in a research note released on Thursday morning,Zacks.com reports.

A number of other equities research analysts also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeMD in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday. BTIG Research lowered their price objective on shares of LifeMD from $18.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday. HC Wainwright cut their target price on shares of LifeMD from $13.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Lake Street Capital reduced their price target on shares of LifeMD from $14.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, LifeMD has a consensus rating of “Hold” and a consensus price target of $9.43.

LifeMD Price Performance

NASDAQ LFMD traded up $0.14 during mid-day trading on Thursday, reaching $3.85. 1,131,816 shares of the stock were exchanged, compared to its average volume of 1,543,392. The stock has a market cap of $185.32 million, a P/E ratio of -22.65 and a beta of 1.57. LifeMD has a one year low of $3.43 and a one year high of $15.84. The stock has a 50 day simple moving average of $5.88 and a 200-day simple moving average of $8.59.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Monday, November 17th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The business had revenue of $60.17 million during the quarter, compared to analysts’ expectations of $62.07 million. During the same period in the prior year, the firm posted $0.09 EPS. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts anticipate that LifeMD will post -0.56 EPS for the current fiscal year.

Insider Buying and Selling at LifeMD

In other news, insider Nicholas P. Alvarez sold 75,000 shares of LifeMD stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $5.92, for a total transaction of $444,000.00. Following the completion of the transaction, the insider directly owned 605,000 shares in the company, valued at $3,581,600. This trade represents a 11.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 18.40% of the company’s stock.

Hedge Funds Weigh In On LifeMD

Hedge funds have recently added to or reduced their stakes in the stock. CWM LLC increased its holdings in LifeMD by 17.5% during the 1st quarter. CWM LLC now owns 9,050 shares of the company’s stock worth $49,000 after purchasing an additional 1,351 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in shares of LifeMD by 148.5% during the second quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company’s stock valued at $50,000 after buying an additional 2,185 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in LifeMD by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock worth $270,000 after buying an additional 2,235 shares in the last quarter. Tower Research Capital LLC TRC raised its position in LifeMD by 110.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after buying an additional 2,452 shares during the last quarter. Finally, Uniplan Investment Counsel Inc. boosted its holdings in LifeMD by 0.8% during the 1st quarter. Uniplan Investment Counsel Inc. now owns 388,288 shares of the company’s stock worth $2,112,000 after acquiring an additional 3,035 shares during the last quarter. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.